富士製薬工業(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4554/E00975 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2023/07/14 | 日証協 | 269,710株 | +2.84% | 64,396株 | +29.86% | 481,216株 | +1.82% | 196,621株 | -1.63% |
2023/07/07 | 日証協 | 262,251株 | -2.87% | 49,589株 | -34.38% | 472,602株 | +0.29% | 199,880株 | -10.61% |
2023/06/30 | 日証協 | 270,013株 | -1.21% | 75,575株 | +135.52% | 471,245株 | -2.6% | 223,605株 | -2.74% |
2023/06/23 | 日証協 | 273,313株 | -13.84% | 32,088株 | -34.29% | 483,840株 | -5.14% | 229,913株 | -3.29% |
2023/06/16 | 日証協 | 317,213株 | -3.03% | 48,832株 | -31.22% | 510,036株 | -0.72% | 237,732株 | -2.17% |
2023/06/09 | 日証協 | 327,140株 | +1.9% | 70,998株 | +20.34% | 513,731株 | +2.01% | 243,003株 | +70.65% |
2023/06/02 | 日証協 | 321,035株 | -9.52% | 58,998株 | +11.13% | 503,630株 | -2.4% | 142,400株 | -2.53% |
2023/05/26 | 日証協 | 354,824株 | -2.31% | 53,088株 | -66.56% | 516,039株 | +4.35% | 146,100株 | +43.25% |
2023/05/19 | 日証協 | 363,224株 | +24.34% | 158,757株 | -42.94% | 494,534株 | -0.88% | 101,990株 | -18.28% |
2023/05/12 | 日証協 | 292,118株 | +301.77% | 278,205株 | +650.12% | 498,920株 | +5.08% | 124,798株 | +34.57% |
2023/05/02 | 日証協 | 72,708株 | +18.4% | 37,088株 | -33.16% | 474,810株 | +5.63% | 92,741株 | -50.08% |
2023/04/28 | 日証協 | 61,408株 | +51.59% | 55,489株 | +336.51% | 449,510株 | +0.94% | 185,781株 | +132.6% |
2023/04/21 | 日証協 | 40,508株 | -11.38% | 12,712株 | -30.18% | 445,314株 | -0.63% | 79,870株 | -1.78% |
2023/04/14 | 日証協 | 45,708株 | -1.06% | 18,208株 | -63.8% | 448,144株 | -2.5% | 81,320株 | -55.32% |
2023/04/07 | 日証協 | 46,200株 | +63.83% | 50,300株 | +222.44% | 459,648株 | +86.91% | 182,010株 | -52.27% |
2023/03/31 | 日証協 | 28,200株 | -61.41% | 15,600株 | +22.67% | 245,918株 | -39.31% | 381,331株 | +293% |
2023/03/24 | 日証協 | 73,077株 | +0.83% | 12,717株 | -31.17% | 405,184株 | +19.28% | 97,030株 | +13.2% |
2023/03/17 | 日証協 | 72,477株 | -61.16% | 18,477株 | +47.82% | 339,684株 | -0.17% | 85,715株 | +234.37% |
2023/03/10 | 日証協 | 186,600株 | -42.5% | 12,500株 | -30.56% | 340,265株 | -19.38% | 25,635株 | -40.76% |
※株式分割は考慮していませんのでご注意ください。
Page Top